About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Journal of Scleroderma and Related Disorders
›
Top Articles
Journal of Scleroderma and Related Disorders
1.8
(top 50%)
impact factor
236
(top 50%)
papers
2.6K
(top 50%)
citations
22
(top 20%)
h
-index
1.9
(top 50%)
impact factor
340
all documents
2.9K
doc citations
42
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis
Journal of Scleroderma and Related Disorders
2017
321
2
Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities
Journal of Scleroderma and Related Disorders
2017
243
3
Gastrointestinal manifestations of systemic sclerosis
Journal of Scleroderma and Related Disorders
2016
106
4
Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis
Journal of Scleroderma and Related Disorders
2017
102
5
Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes
Journal of Scleroderma and Related Disorders
2016
73
6
Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition
Journal of Scleroderma and Related Disorders
2017
62
7
The Mighty Fibroblast and Its Utility in Scleroderma Research
Journal of Scleroderma and Related Disorders
2017
57
8
Pathogenesis of systemic sclerosis associated interstitial lung disease
Journal of Scleroderma and Related Disorders
2020
53
9
The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib
Journal of Scleroderma and Related Disorders
2020
51
10
Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials
Journal of Scleroderma and Related Disorders
2020
43
11
Systemic sclerosis trial design moving forward
Journal of Scleroderma and Related Disorders
2016
42
12
Emerging strategies for treatment of systemic sclerosis
Journal of Scleroderma and Related Disorders
2016
41
13
Update on morbidity and mortality in systemic sclerosis–related interstitial lung disease
Journal of Scleroderma and Related Disorders
2021
39
14
Natural history of systemic sclerosis–related interstitial lung disease: How to identify a progressive fibrosing phenotype
Journal of Scleroderma and Related Disorders
2020
34
15
Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: A SCTC vascular working group report
Journal of Scleroderma and Related Disorders
2018
33
16
Kidney involvement in systemic sclerosis: From pathogenesis to treatment
Journal of Scleroderma and Related Disorders
2018
32
17
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease
Journal of Scleroderma and Related Disorders
2019
31
18
The Critical Need for Accurately Defining Digital Ulcers in Scleroderma
Journal of Scleroderma and Related Disorders
2017
29
19
Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis
Journal of Scleroderma and Related Disorders
2017
27
20
Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design
Journal of Scleroderma and Related Disorders
2018
27
21
Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era
Journal of Scleroderma and Related Disorders
2017
26
22
Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up
Journal of Scleroderma and Related Disorders
2017
25
23
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition
Journal of Scleroderma and Related Disorders
2022
25
24
Systemic sclerosis-related calcinosis
Journal of Scleroderma and Related Disorders
2016
24
25
Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis
Journal of Scleroderma and Related Disorders
2020
24
26
Antisynthetase syndrome: A distinct disease spectrum
Journal of Scleroderma and Related Disorders
2020
24
27
Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients
Journal of Scleroderma and Related Disorders
2017
23
28
Advances in nailfold capillaroscopic analysis in systemic sclerosis
Journal of Scleroderma and Related Disorders
2018
23
29
Update on assessment and management of primary cardiac involvement in systemic sclerosis
Journal of Scleroderma and Related Disorders
2018
23
30
Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis
Journal of Scleroderma and Related Disorders
2018
22
31
Mechanistic and clinical insights at the scleroderma-cancer interface
Journal of Scleroderma and Related Disorders
2017
21
32
Musculoskeletal Involvement in Systemic Sclerosis: An Unexplored Aspect of the Disease
Journal of Scleroderma and Related Disorders
2017
21
33
Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States
Journal of Scleroderma and Related Disorders
2018
21
34
Limited cutaneous systemic sclerosis: the unfairly neglected subset
Journal of Scleroderma and Related Disorders
2016
20
35
Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort
Journal of Scleroderma and Related Disorders
2019
20
36
Nailfold capillaroscopy in systemic sclerosis – state of the art: The evolving knowledge about capillaroscopic abnormalities in systemic sclerosis
Journal of Scleroderma and Related Disorders
2019
20
37
The role of ultrasound in systemic sclerosis: On the cutting edge to foster clinical and research advancement
Journal of Scleroderma and Related Disorders
2021
20
38
What have multicentre registries across the world taught us about the disease features of systemic sclerosis?
Journal of Scleroderma and Related Disorders
2017
18
39
Raynaud’s phenomenon
Journal of Scleroderma and Related Disorders
2019
18
40
Angiostatic and Angiogenic Chemokines in Systemic Sclerosis: An Overview
Journal of Scleroderma and Related Disorders
2017
17
41
Review of local wound management for scleroderma-associated digital ulcers
Journal of Scleroderma and Related Disorders
2018
17
42
COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
Journal of Scleroderma and Related Disorders
2021
17
43
Controversies: molecular vs. clinical systemic sclerosis classification
Journal of Scleroderma and Related Disorders
2016
16
44
Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis
Journal of Scleroderma and Related Disorders
2018
15
45
Why, how, and when to use color Doppler ultrasound for improving precision in the diagnosis, assessment of severity and activity in morphea
Journal of Scleroderma and Related Disorders
2019
15
46
Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease
Journal of Scleroderma and Related Disorders
2016
14
47
Updates on animal models of systemic sclerosis
Journal of Scleroderma and Related Disorders
2016
14
48
Clinical significance and usefulness of rehabilitation for systemic sclerosis
Journal of Scleroderma and Related Disorders
2018
14
49
Circulating biomarkers of systemic sclerosis – interstitial lung disease
Journal of Scleroderma and Related Disorders
2020
14
50
Patient-reported outcome instruments in clinical trials of systemic sclerosis
Journal of Scleroderma and Related Disorders
2020
14
site/software ©
exaly
; All materials licenced under
CC by-SA
.